Latest News

You can find our latest news below

01 Oct, 2020

Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.

01 Oct, 2020

In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.

17 Sep, 2020

We are pleased to let you know that we are developing several monoclonal antibodies specific to SARS-CoV2 nucleoproteins (Cat.# 3CV4) and to Spike RBD (Cat.# 3CV2).

17 Sep, 2020

By watching this webinar, you will learn about:
- transmission and clinical characteristics of SARS-CoV-2
- the existing testing methods for SARS-CoV-2, including nucleic acid testing, genome sequencing, serological testing for SARS-CoV-2 specific antibodies and antigen testing
- the principles, advantages and limitations of these testing methods
- safety precautions for handling different types of clinical specimens for SARS-CoV-2 detection

26 Aug, 2020

HyTest’s SARS-CoV-2 Nucleoprotein (Cat.# 8COV3) is a full-length recombinant antigen that can be used in serology assays for the detection of COVID-19 specific antibodies.

26 Aug, 2020

Soluble ST2 (sST2) biomarker is used for additive risk stratification and prognosis of patients with heart failure (HF). ST2 interacts with IL-33, and IL-33/ST2 system is upregulated in cardiomyocytes and fibroblasts in response to cardiac injury or cardiac stress.

11 Jul, 2020

HyTest’s recombinant SARS-CoV-2 Spike RBD is now available. The antigen can be used in the development of COVID-19 serology (antibody) tests.

02 Jul, 2020

We are finalizing the development of SARS-CoV-2 Nucleoprotein. The antigen can be used in serology assays.

25 Jun, 2020

We have now developed a recombinant GFAP protein that can be used as a standard or calibrator in GFAP immunoassay development

24 Jun, 2020

Insulin-like growth factor binding protein-4 (IGFBP-4) fragments have been shown to predict the risk of major adverse cardiovascular events, including segment-elevation myocardial infarction, in patients with acute coronary syndrome.

02 Jun, 2020

We are finalizing the development of SARS-Cov-2 Spike RBD recombinant antigen.

27 May, 2020

In dogs, C-reactive protein (CRP) can be used as a marker of inflammation. Its concentration in blood increases rapidly in systemic inflammation and decreases quickly during recovery. It has been shown to increase in disorders such as bacterial infections, sepsis and pyometra, as well as in the case of post-surgical infections.

27 May, 2020

Prof. Fred S. Apple (Hennepin Healthcare/Hennepin County Medical Center, Laboratory Medicine and Pathology, and University of Minnesota School of Medicine, Minneapolis MN, US) is the winner of the 2020 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics, sponsored by HyTest. This award honors an individual who has undertaken remarkable scientific work with cardiac markers or immunodiagnostic applications to improve cardiac disease diagnosis.

27 May, 2020

We will attend the 17th China Association of Clinical Laboratory Practice Expo held at Nanchang Greenland International Expo Center, on 21-23 August.

29 Apr, 2020

The cardiac isoform of Troponin I (cTnI) is used as a gold standard as marker of acute myocardial infarction (AMI). The region 24-40 aar of cTnI is a perspective target for monoclonal antibodies (MAb), because it is less affected by the action of autoantibodies and is not hindered by the other components of troponin complex.

16 Apr, 2020

By watching this webinar, you will learn about: 
- the use of nucleic acid testing and serological testing for diagnostics of COVID-19, as well as the benefits and limitations of these methods for COVID-19 diagnostics
- the effects of SARS-CoV-2 on the cardiovascular system
- the role of cardiac and inflammatory biomarkers in distinguishing the severity and prognosis of COVID-19


13 Mar, 2020

The World Health Organization (WHO) declared the Coronavirus outbreak a pandemic on Wednesday, March 11, and we are very closely following the changing situation on a daily basis. We would like to confirm to you that we are continuing to supply our products as normal.

26 Feb, 2020

Heart failure is a severe health problem that is characterized by an increasing prevalence and economic cost.

14 Feb, 2020

How can we make cancer research, treatment and life with cancer better? Read more and join the contest

31 Jan, 2020

HyTest Shanghai has decided to cancel the opening ceremony of the new premises scheduled for the end of February 2020 due to the epidemic situation in China

Do you need samples?

We are happy to make you an offer